CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
77.66
+1.05 (+1.37%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close76.61
Open77.00
Bid0.00 x 1800
Ask0.00 x 900
Day's Range76.53 - 77.72
52 Week Range74.13 - 147.17
Volume6,140,587
Avg. Volume7,490,814
Market Cap56.407B
Beta1.31
PE Ratio (TTM)21.34
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Analysts Split: Celgene Tilts 'To Greater Risk' On Revlimid Challenges
    Investor's Business Daily10 hours ago

    Analysts Split: Celgene Tilts 'To Greater Risk' On Revlimid Challenges

    Wall Street was split Wednesday on Celgene as one sell-side analyst downgraded the stock saying it "has tilted to greater risk" while another upgraded shares.

  • Motley Fool17 hours ago

    David's 5 Winning Stocks for a Thinking World: 2 Years Later, Has a Bet on Brains Paid Off?

    It's been two years since David's picked a batch of stocks made to thrive in a global society that's ever more focused on the life of the mind.

  • Benzinga17 hours ago

    Celgene Wins One Bull, Loses Another On Revlimid Potential

    Bernstein analyst Aaron Gal upgraded Celgene from Market-Perform to Outperform and cut the price target from $121 to $102. By Bernstein’s assessment, Celgene’s current discounted cash flow reflects the worst possible outcome for the Revlimid trial — a result that could push the launch to April 2020. Toung is less optimistic about Revlimid’s legal issues, which could increase share volatility with an adverse ruling.

  • Celgene Cratering to Four-Year Low Leaves Analysts Split
    Bloomberg17 hours ago

    Celgene Cratering to Four-Year Low Leaves Analysts Split

    Celgene Corp. sell-side analysts can’t agree on what’s next for the company with shares hovering near a four-year low. Argus analyst David Toung moved to the sidelines on a risk-reward that has “tilted to greater risk” given an over-reliance on one of the world’s biggest brand-name cancer treatments, Revlimid. Shares tumbled on Monday to a four-year low after a news article about the departure of its former business development head, George Golumbeski, added gasoline to the fire of concerns for the drugmaker.

  • Warren Buffett's Mentor Was Right About the Crazy Market -- and 2 Biotech Stocks Prove It
    Motley Fool17 hours ago

    Warren Buffett's Mentor Was Right About the Crazy Market -- and 2 Biotech Stocks Prove It

    The reaction to news from Celgene and Insys demonstrates an undeniable truth: Mr. Market can be very irrational at times.

  • Why Amgen's In Trouble — And Should Take Notes From Biogen, Celgene
    Investor's Business Dailyyesterday

    Why Amgen's In Trouble — And Should Take Notes From Biogen, Celgene

    Amgen trades at a premium to biotech companies Celgene and Biogen, but analysts are worried its pipeline contains fewer blockbuster opportunities.

  • Celgene Corporation: How to Effectively Buy Into CELG Stock
    InvestorPlace2 days ago

    Celgene Corporation: How to Effectively Buy Into CELG Stock

    After years of growth, Celgene Corporation (NASDAQ:CELG) has spent the past eight months suffering from ever-weakening price action. In fact and with shares of Celgene now off a full 50% from 2017’s all-time-highs following Monday’s 4.70% price drop, you could say bears have been acting with barely any hesitation in CELG stock. The latest ‘disappointment’ in shares of Celgene, judging by Monday’s price reaction, is a report that Celgene’s top dog of business development discreetly retired over a month ago.

  • Benzinga2 days ago

    Celgene Forges Oncology Partnership With Germany's Evotec

    Celgene Corporation (NASDAQ: CELG ) — which is recently very much in the news, although for dubious reasons — has struck a partnership with Germany's Evotec AG (ADR) (OTC: EVTCY ), which partners with ...

  • Motley Fool2 days ago

    Reviewing 5 Winning Stocks for a Thinking World, and Relishing 1 Thoughtful CEO

    First we gauge the performance of David’s recommendations. Then, he interviews Middleby Corp.'s remarkable leader, Selim Bassoul.

  • What’s Behind the 28% Hike in SCYNEXIS Stock Last Week?
    Market Realist2 days ago

    What’s Behind the 28% Hike in SCYNEXIS Stock Last Week?

    SCYNEXIS (SCYX) witnessed a 28% rise in its stock price in the week ended May 18. On May 18, SCYNEXIS stock closed at $1.63, which is ~14.4% growth from its previous close of $1.43 on May 17. SCYNEXIS stock rose ~27% over the last month. SCYNEXIS is a biotechnology company focused on the development of innovative therapies for the treatment of patients with difficult-to-treat and life-threatening infections.

  • Fifth Third Bancorp and Celgene: Top Losses on May 21
    Market Realist2 days ago

    Fifth Third Bancorp and Celgene: Top Losses on May 21

    The S&P 500’s top losses on May 21 were: Fifth Third Bancorp (FITB) declined 7.9%. Celgene (CELG) declined 4.7%. Symantec (SYMC) declined 2.7%. Allergan (AGN) declined 2.7%. Campbell Soup (CPB) declined 2.3%. Fifth Third Bancorp

  • Investopedia2 days ago

    Celgene Strikes Strategic Partnership With Evotec

    U.S. biotechnology company Celgene Corp. ( CELG) has entered into a long-term strategic drug discovery and development partnership with Hamburg, Germany-based Evotec AG. In a brief statement, Evotec said it will receive an upfront payment of $65 million for its role in the partnership, as well as the potential to earn “significant milestone payments” and “tiered royalties” on each licensed program. Celgene and Evotec have already partnered up before.

  • 3 Biotechs on the FDA's Naughty List That Should Be on Investors' Buy Lists
    Motley Fool2 days ago

    3 Biotechs on the FDA's Naughty List That Should Be on Investors' Buy Lists

    The FDA might be down on these biotechs, but investors shouldn't be.

  • Celgene Plunges On Report Its Head Of Mergers Quietly Exited In April
    Investor's Business Daily2 days ago

    Celgene Plunges On Report Its Head Of Mergers Quietly Exited In April

    Celgene plunged to another four-year low Monday on a report that an executive in charge of business development quietly retired in mid-April.

  • 5 Top Stock Trades for Tuesday Morning
    InvestorPlace2 days ago

    5 Top Stock Trades for Tuesday Morning

    U.S. stocks jumped higher Monday on news that trade tensions between China and the U.S. are cooling off. Can stocks continue higher this week? Here are our top stock trades for Tuesday. Top Stock Trades for Tomorrow #1: Celgene (CELG)

  • Did Celgene Corporation’s (NASDAQ:CELG) Recent Earnings Growth Beat The Trend?
    Simply Wall St.3 days ago

    Did Celgene Corporation’s (NASDAQ:CELG) Recent Earnings Growth Beat The Trend?

    For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.Read More...

  • These Stocks Have Quadrupled in Just 1 Year
    Motley Fool5 days ago

    These Stocks Have Quadrupled in Just 1 Year

    Find out how these companies have defied a choppy market.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool5 days ago

    3 Top Biotech Stocks to Buy Right Now

    Want to invest in this promising industry but don't know where to start? Here are three stocks that can get the ball rolling.

  • FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs
    InvestorPlace5 days ago

    FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs

    The Food and Drug Administration (FDA) announced a shame list of companies that try to block generic drugs in order to ramp up profits.

  • Amgen Stock Rises over 2% on Drug Approvals
    Market Realist6 days ago

    Amgen Stock Rises over 2% on Drug Approvals

    On May 17, Amgen (AMGN) stock rose ~0.5% to the closing price of $174.65 per share following FDA approval of Aimovig. The company’s stock price has risen ~2.3% in the last week following recent drug approvals. Amgen’s stock price has risen ~11.2% over the last 12 months.

  • BlueBird Bio Stock Jumps over 6% on May 17
    Market Realist6 days ago

    BlueBird Bio Stock Jumps over 6% on May 17

    BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.

  • Jounce Therapeutics Gets Throttled, Loses 35% Today
    Motley Fool6 days ago

    Jounce Therapeutics Gets Throttled, Loses 35% Today

    The clinical-stage upstart reported disappointing news that sparked pessimism.

  • FDA names drugmakers accused of blocking cheaper generics
    Associated Press6 days ago

    FDA names drugmakers accused of blocking cheaper generics

    TRENTON, N.J. (AP) — U.S. drug regulators are publicizing information on brand-name drugmakers that use what government officials call "gaming tactics" to block cheaper copycat versions.

  • The FDA Is Trying To 'Shame' Celgene, Gilead — Here's Why It Won't Work
    Investor's Business Daily6 days ago

    The FDA Is Trying To 'Shame' Celgene, Gilead — Here's Why It Won't Work

    Celgene toppled to a four-year low Thursday after it appeared on a list from the FDA attempting to "shame" drugmakers working to block generic competition.

  • NYSE trader: Expect explosive earnings growth over the next 4-5 quarters
    Yahoo Finance Video6 days ago

    NYSE trader: Expect explosive earnings growth over the next 4-5 quarters

    Keith Bliss of Cuttone and Company joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.